Experience of outpatient follow-up of heart transplant recipients at Shumakov center

Heart transplantation (HT) is considered the optimal therapy for end-stage heart failure. In recent years, the number of operations performed has been growing, which has led to a rise in the number of heart transplant recipients requiring outpatient follow-up.

Objective: to evaluate the effectiveness of the model of dual personalized follow-up of heart transplant recipients in the consultative and diagnostic department of Shumakov National Medical Research Center of Transplantology and Artificial Organs.

Materials and methods. The study included 1,436 patients under outpatient follow-up from January 2008 to December 2022. Recipient data, results of laboratory and instrumental examination methods, nature and frequency of complications at different follow-up periods were analyzed.

Results: At the time of discharge from the hospital, 98.7% of patients had received triple-drug immunosuppressive therapy; 6 months later, methylprednisolone was discontinued in 72.2% of recipients. Mean tacrolimus level during the 1-year follow-up was 8.7 ± 2.7 ng/mL; in the period from 1 to 5 years of followup, the mean was 5.1 ± 2.4 ng/mL. At year 1 after transplantation, 23 (1.7%) recipients had been converted to everolimus; by the end of year 5 of follow-up, the number had increased to 8.6%. The most frequently detected complications during outpatient follow-up were: hypertension (48.65%), post-transplant diabetes mellitus (7.24%), nephropathy (35.97%), and malignant neoplasms (4.2%). Recipient survival, excluding in-hospital mortality, was 96.5%; and 88.0% at year 1 and 5 of follow-up, respectively.

Conclusion: The dual personalized approach model for outpatient follow-up and treatment of heart transplant recipients will improve recipient survival and quality of life in the long-term post-HT period.

1. Transplantologiya: rukovodstvo dlya vrachej. Pod red. V.I. Shumakova. 2-e izd., ispr. i dop. M.: MIA, 2006; 544.

2. Transplantologiya: itogi i perspektivy. Tom XIII. 2021 god. Pod red. S.V. Gautier. M.–Tver’: Triada, 2022; 416.

3. Gautier SV, Shevchenko AO, Popcov VN. Pacient s transplantirovannym serdcem. M.–Tver’: Triada, 2014: 144.

4. Shevchenko AO, Nikitina EA, Mozheiko NP, Tyunyaeva IYu, Koloskova NN. Prevalence and predictors of hypertension in cardiac recipients. Russian Journal of Transplantology and Artificial Organs. 2017; 19 (3): 33–39. (In Russ.). https://doi.org/10.15825/1995-1191-2017-3-33-39.

5. Poptsov VN, Zolotova EN. Heart transplantation in diabetic recipients. Russian Journal of Transplantology and Artificial Organs. 2018; 20 (1): 120–126. (In Russ.). https://doi.org/10.15825/1995-1191-2018-1-120-126.

6. Sakhovsky SA, Koloskova NN, Goncharova AYu, Mironkov BL. Intravascular visualization methods in estimating vasculopathy of a transplanted heart. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (1): 165–168. (In Russ.). https://doi.org/10.15825/1995-1191-2019-1-165-168.

7. Koloskova NN. Medicated therapy with transplanted heart recipients: … M.D. 14.01.24. M., 2020; 212.